Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
• Patients refractory to conventional disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumor necrosis factor (TNF)-alpha agents often have limited treatment options.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab in patients with active RA who are refractory to standard therapies.
• To assess the impact of rituximab on disease activity, physical function, and quality of life in this patient population.

Main Methods:

• Adult patients with active RA, meeting specific criteria (positive RF/anti-CCP, joint counts, inflammatory markers), were enrolled.
• Patients received intravenous rituximab infusions (1000 mg on days 1 and 15).
• Disease activity (DAS28, TJC, SJC, ESR, CRP), physical function (HAQ-DI), quality of life (SF-36), and fatigue were assessed over 24 weeks.

Main Results:

• Significant reductions in tender and swollen joint counts, ESR, and CRP were observed at 24 weeks.
• Patient-reported outcomes improved, including decreased disability (HAQ-DI) and enhanced quality of life (SF-36).
• Sixty percent achieved EULAR moderate-to-good response, and 50% achieved ACR20 response, with minimal infusion reactions.

Conclusions:

• Rituximab demonstrates significant efficacy in improving clinical and patient-reported outcomes for patients with refractory RA.
• The treatment is well-tolerated, indicating its potential as a valuable therapeutic option for this challenging patient group.